ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has ImmunoGen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMGN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: IMGN's weekly volatility (7%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: IMGN exceeded the US Biotechs industry which returned 23.1% over the past year.
Return vs Market: IMGN exceeded the US Market which returned 39.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is ImmunoGen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShareholders May Not Be So Generous With ImmunoGen, Inc.'s (NASDAQ:IMGN) CEO Compensation And Here's Why
1 week ago | Simply Wall StImmunoGen (NASDAQ:IMGN) Shareholders Booked A 79% Gain In The Last Five Years
2 months ago | Simply Wall StHow Much Of ImmunoGen, Inc. (NASDAQ:IMGN) Do Institutions Own?
Is ImmunoGen undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: IMGN ($6.69) is trading below our estimate of fair value ($23.57)
Significantly Below Fair Value: IMGN is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: IMGN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: IMGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMGN is overvalued based on its PB Ratio (14.2x) compared to the US Biotechs industry average (3.4x).
How is ImmunoGen forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: IMGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: IMGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: IMGN's revenue (50.5% per year) is forecast to grow faster than the US market (9.4% per year).
High Growth Revenue: IMGN's revenue (50.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMGN's Return on Equity is forecast to be high in 3 years time
How has ImmunoGen performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMGN is currently unprofitable.
Growing Profit Margin: IMGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMGN is unprofitable, but has reduced losses over the past 5 years at a rate of 12% per year.
Accelerating Growth: Unable to compare IMGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-7.7%).
Return on Equity
High ROE: IMGN has a negative Return on Equity (-52.42%), as it is currently unprofitable.
How is ImmunoGen's financial position?
Financial Position Analysis
Short Term Liabilities: IMGN's short term assets ($319.6M) exceed its short term liabilities ($134.4M).
Long Term Liabilities: IMGN's short term assets ($319.6M) exceed its long term liabilities ($117.5M).
Debt to Equity History and Analysis
Debt Level: IMGN's debt to equity ratio (2.2%) is considered satisfactory.
Reducing Debt: IMGN had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMGN has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMGN has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 3.2% each year.
What is ImmunoGen current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mark Enyedy (56 yo)
Mr. Mark Joseph Enyedy is Non-Executive Director at Ergomed plc since June 10, 2021. He has been the Chief Executive Officer and President at ImmunoGen, Inc. since May 16, 2016 and served as its Interim Pr...
CEO Compensation Analysis
Compensation vs Market: Mark's total compensation ($USD4.60M) is about average for companies of similar size in the US market ($USD3.72M).
Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.
Experienced Management: IMGN's management team is not considered experienced ( 2 years average tenure), which suggests a new team.
Experienced Board: IMGN's board of directors are considered experienced (9.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 14.6%.
ImmunoGen, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: ImmunoGen, Inc.
- Ticker: IMGN
- Exchange: NasdaqGS
- Founded: 1980
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$1.338b
- Shares outstanding: 199.94m
- Website: https://www.immunogen.com
Number of Employees
- ImmunoGen, Inc.
- 830 Winter Street
- United States
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/18 23:32|
|End of Day Share Price||2021/06/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.